NEW YORK (GenomeWeb News) — Transgenomic today said it will analyze cancer pathway genes for OSI Pharmaceuticals using a high-throughput methodology it developed for characterizing gene variants in malignant tumors.
 
Transgenomic said its high-throughput scanning offers forward and reverse Sanger sequencing and variant annotation to detect the mutations, and that it will be used to help OSI in its cancer drug-development programs.
 
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.